Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Inclusion Criteria: * Written informed consent * HBsAg-positive candidates for HBV-related liver transplant * Treatment with antiviral therapy before transplantation as per treating physician's recommendation. (NOTE: It is expected that most patients will receive Lamivudine or Adefovir Dipivoxil pre-transplant. In the case of antiviral resistance, an effective alternative antiviral agent(s) must be used.) Exclusion Criteria: * Multi-organ transplantation recipients * Liver re-transplantation except for primary non-function * Presence of a hepatoma (larger than 5.0 cm as a solitary node) or 2 to 3 multi-focal nodes (larger than 3.0 cm each) (Milan Criteria) based on information available at baseline visit (CT scan, MRI). * Patients requiring an OLT (Orthotopic Liver Transplant)due to fulminant hepatitis B * OLT patients receiving a liver graft from a donor that is positive for HBsAg * Patients using interferon pre-transplant (as interferon cannot be used post-transplant) * History of IgA (immunoglobulin A) deficiency * History of hypersensitivity to blood products. * HIV or HCV positive * Use of an investigational product, or participation in another clinical trial during the course of the study (with the exception of quality-of-life or repository studies) * Pregnancy or planned pregnancy during the course of the study